Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden
Crossref DOI link: https://doi.org/10.1007/s40119-015-0041-3
Published Online: 2015-06-23
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Begum, Najida
Stephens, Stephanie
Schoeman, Olaf
Fraschke, Anina
Kirsch, Bodo
Briere, Jean-Baptiste
Verheugt, Freek W. A.
van Hout, Ben A.